| Patents for A61K 49 - Preparations for testing in vivo (35,376) |
|---|
| 04/02/2009 | US20090087383 Nanoparticle-based imaging agents for x-ray/computed tomography and methods for making same |
| 04/02/2009 | US20090087382 Contrast agents and methods for preparing contrast agents |
| 04/02/2009 | US20090087381 Chelator-functionalized nanoparticles |
| 04/02/2009 | US20090087380 Polymer devices for therapeutic applications |
| 04/02/2009 | US20090087377 Compositions for targeted imaging and therapy |
| 04/02/2009 | US20090087376 Heterocyclic Dye Compounds For In Vivo Imaging And Diagnosis Of Alzheimer's Disease |
| 04/01/2009 | EP2042518A2 Dual specificity antibodies and methods of making and using |
| 04/01/2009 | EP2040752A2 Core-shell nanoparticles for thearapy and imaging purposes |
| 04/01/2009 | EP2040699A2 Methods and compositions for diagnostic and therapeutic targeting of cox-2 |
| 04/01/2009 | EP1357971A4 Regulation of eating habits |
| 04/01/2009 | EP1292613B9 Chimeric GPF-Aequorin as bioluminiscent Ca++ reporters at the single cell level |
| 04/01/2009 | CN101400371A Chelating conjugates having a substituted aromatic moiety and derivatives thereof |
| 04/01/2009 | CN101400370A Method to assess surfactant adsorption on skin |
| 04/01/2009 | CN101400369A Novel colored solutions of injectable drugs and their pharmaceutically acceptable salts |
| 03/31/2009 | US7510853 Exhibiting similarity to cytokine; isolated or recombinant polynucleotide encoding antigenic polypeptide of sequence 2 |
| 03/31/2009 | US7510825 Detecting perturbations and alterations of the normal organization of the cell plasma membrane (PNOM)-cells within a population of cells using a "perturbed membrane-binding compound" (PMBC) of given formula; e.g. monitoring aggressiveness of a tumor |
| 03/31/2009 | US7510718 Expression vector comprising nucleotide sequences coding multimeric nuclear anchoring-protein for use as tool in transfer, expression and propagation of heterologous gene sequences |
| 03/31/2009 | US7510700 Pathological tissue detection and treatment employing targeted benzoindole optical agents |
| 03/31/2009 | US7510699 In vivo fluorescence sensors, systems, and related methods operating in conjunction with fluorescent analytes |
| 03/31/2009 | CA2294502C Use of intravenous contrast media for projection mammography |
| 03/26/2009 | WO2009039310A2 Light inhibitors for asthma, lung and airway inflammation, respiratory, interstitial, pulmonary and fibrotic disease treatment |
| 03/26/2009 | WO2009038779A2 Methods and compositions for inhibiting undesirable cellular proliferation by targeted liposome delivery of active agents |
| 03/26/2009 | WO2009037857A1 Diagnostic agent and therapeutic agent for lung cancer, prostate cancer, breast cancer, ovarian cancer or melanoma |
| 03/26/2009 | WO2009037342A2 Formulation comprising contrast agents for mri comprising an organic polybase |
| 03/26/2009 | WO2009037251A2 Coordination complex of a metal and a polymer incorporating phosphorus atoms and uses employing such a complex |
| 03/26/2009 | WO2009036885A1 Ed-b fibronectin as stratification marker for anti-tumor drugs |
| 03/26/2009 | WO2009036566A1 Methods for detecting abnormalities in breast tissue using aromatase inhibitors |
| 03/26/2009 | WO2008143633A3 Compounds and methods for treatment of alpha-1 antitrypsin deficiency |
| 03/26/2009 | WO2005048917A3 Use of epha4 and modulator or epha4 for diagnosis, treatment and prevention of cancer |
| 03/26/2009 | US20090083866 Transgenic rosa26-luciferase mice for bioluminescent imaging |
| 03/26/2009 | US20090082547 Compositions for enhancing transport of molecules into cells |
| 03/26/2009 | US20090081722 Site-specific labeling of affinity tags in fusion proteins |
| 03/26/2009 | US20090081130 Microparticles useful as ultrasonic contrast agents and for delivery of drugs into the bloodstream |
| 03/26/2009 | US20090081129 Bioluminescent Endoscopy Methods And Compounds |
| 03/26/2009 | US20090081128 Model of Alzheimer's Disease |
| 03/26/2009 | US20090081124 Virus coat protein/receptor chimeras and methods of use |
| 03/26/2009 | CA2698616A1 Ed-b fibronectin as stratification marker for anti-tumor drugs |
| 03/25/2009 | EP2040063A1 Resilient containers for hyperpolarized gases |
| 03/25/2009 | EP1492452A4 System, formulation, kit and method for tagging colonic residue in an individual |
| 03/25/2009 | EP1380295B1 Photosensitiser and method for production thereof |
| 03/25/2009 | CN201211237Y Phototoxic action test detection device |
| 03/25/2009 | CN101395228A Quinaldine based semisquaraines and squaraine dyes, process for preparation thereof and use thereof |
| 03/25/2009 | CN101391106A Fruity flavor barium meal |
| 03/25/2009 | CN101390746A Elastic vertical compression type pain quantitative determination instrument |
| 03/24/2009 | US7507871 Rat model of diabetic nephropathy |
| 03/24/2009 | US7507764 Amphiphilic [5:1]- and [3:3]- hexakisadducts of fullerenes |
| 03/24/2009 | US7507727 Drug screening for antiproliferative agents based on quadraplex structure formation; disorders based on oncogene such as c-Myc overexpression; use of e.g. fused ring compounds based on 1,4-benzoxazino(2,3,4-ij)quinolin-4-one for example |
| 03/24/2009 | US7507537 Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| 03/24/2009 | US7507407 Immunoliposomes that optimize internationalization into target cells |
| 03/24/2009 | US7507395 Include pH-sensitive fluorescent and fluorogenic 2',7'-dialkylfluorescein derivatives and associated nonfluorescent precursor compounds; malignancy, multidrug resistance, lysosome storage disease, corneal acidosis, ulcer disease, diabetic heart condition, or hyperglycemia |
| 03/24/2009 | US7507394 Treating vascular lesions with a solution comprising biocompatible polymer, a biocompatible solvent for dissolving the polymer and a biocompatible contrast agent |
| 03/24/2009 | CA2450690C Improved chelator conjugates |
| 03/24/2009 | CA2328136C Intramolecularly-quenched near infrared fluorescent probes |
| 03/24/2009 | CA2215997C Biodegradable polyacetal polymers and formation and use |
| 03/19/2009 | WO2009036441A2 Contrast agents |
| 03/19/2009 | WO2009036011A2 Markers for ventricular arrhythmia |
| 03/19/2009 | WO2009035929A2 Cardiovascular and brain cell therapy using intracellular ryanodine receptor modulation by the estrogen receptor beta |
| 03/19/2009 | WO2009035510A1 Biomarker to measure drug efficacy in enteropathic disease |
| 03/19/2009 | WO2009034177A2 Diagnostic substances for optical imaging testing on the basis of nanoparticular formulations |
| 03/19/2009 | WO2008145830A3 Novel pro-fluorescent compounds |
| 03/19/2009 | WO2008143916A3 Prokinetic agent for bowel preparation |
| 03/19/2009 | WO2008125747A3 Fluorescent emulsions for optical imaging |
| 03/19/2009 | WO2008096009A3 Polymorphism in the slc30a8 gene |
| 03/19/2009 | WO2005101993A3 Metal-containing nanolayered composites, and applications thereof |
| 03/19/2009 | US20090076571 MRI-Guided Photodynamic Therapy For Cancer |
| 03/19/2009 | US20090074875 Nanoparticulate compositions having lysozyme as a surface stabilizer |
| 03/19/2009 | US20090074873 Nanoparticulate beclomethasone dipropionate compositions |
| 03/19/2009 | US20090074674 Stabilized, biocompatible gold nanoparticles and enviro-friendly method for making same |
| 03/19/2009 | US20090074673 Compositions and methods for producing cellular labels for nuclear magnetic resonance techniques |
| 03/19/2009 | US20090074672 Tumor Boundary Imaging |
| 03/19/2009 | US20090074671 Drug-immobilized inorganic nanoparticle |
| 03/19/2009 | US20090074670 Hyperthermia Therapeutic Agent Delivery System |
| 03/19/2009 | US20090074669 PNMT as a novel marker for progenitor cells |
| 03/19/2009 | US20090074668 Vldlr-/- mouse models and related methods |
| 03/19/2009 | US20090074667 Diagnostic methods for the detection of risk of neurodevelopmental disorders |
| 03/19/2009 | US20090074665 Diagnosis and treatment of cancer:I |
| 03/19/2009 | US20090074663 Peptide for diagnosing, preventing and treating atherosclerosis and uses thereof |
| 03/19/2009 | US20090074658 Compositions and methods for generating and screening adenoviral libraries |
| 03/19/2009 | CA2699341A1 Diagnostic substances for optical imaging testing on the basis of nanoparticular formulations |
| 03/19/2009 | CA2698359A1 Biomarker to measure drug efficacy in enteropathic disease |
| 03/18/2009 | EP2036925A1 Novel steroid-activated nuclear receptors and uses therefor |
| 03/18/2009 | EP2036577A1 Diagnostic materials for optical image-forming investigation based on nanoparticulate formulations |
| 03/18/2009 | EP2036576A1 ED-B fibronectin as stratification marker for antitumor drugs |
| 03/18/2009 | EP2035082A2 Oxygen therapy with ultrasound |
| 03/18/2009 | EP2035044A2 Elimination of contrast agent concentration dependency in mri |
| 03/18/2009 | EP1819366B1 A staining composition for staining an ophthalmic membrane |
| 03/18/2009 | EP1581262B1 Contrast agent |
| 03/18/2009 | EP1154802B1 Method of measuring physiological function with a dye like fluorescein-polyacrylic acid |
| 03/18/2009 | EP1095136B1 Cells and animals deficient in protein kinase c epsilon |
| 03/18/2009 | CN101389357A Tumor-selective fluorescent dye |
| 03/18/2009 | CN101389356A Drug delivery material |
| 03/18/2009 | CN101389355A Bifunctional resorcinol, thioresorcinol, and dithioresorcinol derivative metal chelating conjugates |
| 03/18/2009 | CN101385663A Method for preparing small-sized mammalian skin rolled and avulsed wound model |
| 03/18/2009 | CN101385662A Method for establishing rat laboratory animal model with prostate interstitial proliferation |
| 03/17/2009 | US7505811 Method and apparatus for examining tissue for predefined target cells, particularly cancerous cells, and a probe useful in such method and apparatus |
| 03/17/2009 | US7504233 Reliable measure of insulin resistance; kits |
| 03/17/2009 | US7504088 Lipophilic derivatives of chelate monoamides |
| 03/17/2009 | US7504087 Receptor-avid exogenous optical contrast and therapeutic agents |
| 03/17/2009 | US7504082 Magnetic nanoparticles comprising Gadolinium and method of fabrication |
| 03/17/2009 | CA2346863C Therapeutic use of polymers |